Veru, Inc. (VERU) CEO Mitchell Steiner on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/10/21
Female Health Company The (VERU) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 02/10/21
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First QuarterGlobeNewsWire • 02/10/21
Veru's COVID-19 Drug Candidate Shows High Relative Reduction In Treatment Failures, Mortality In Mid-Stage StudyBenzinga • 02/08/21
Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeGlobeNewsWire • 02/08/21
Will Female Health Company The (VERU) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 02/03/21
Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10thGlobeNewsWire • 01/27/21
Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021GlobeNewsWire • 01/04/21
Veru's stock soars again on heavy volume after positive results of breast cancer treatmentMarket Watch • 12/14/20
VERU Stock News: 9 Things for Investors to Know About Veru Breast Cancer Trial ResultsInvestorPlace • 12/14/20
Do Options Traders Know Something About Veru (VERU) Stock We Don't?Zacks Investment Research • 12/14/20
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast CancerGlobeNewsWire • 12/14/20
VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast CancerGlobeNewsWire • 12/14/20
Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 12/09/20